Medical devices, healthcare technology and the business of care
PMA decision · P200014

cobas EZH2 Mutation Test

Roche Molecular System, Inc. · Decision date Jun 18, 2020

MEDTECHLEDGER EXPLANATIONP200014

What did the FDA decide?

The FDA approved the cobas EZH2 Mutation Test, a real-time allele-specific PCR test for qualitative detection of specific single nucleotide mutations in the EZH2 gene. The detected mutations are Y646N, Y646F or Y646X (Y646H, Y646S, or Y646C), A682G, and A692V, using DNA extracted from formalin fixed paraffin embedded human follicular lymphoma tumor tissue specimens.

The test is intended to identify follicular lymphoma patients with an EZH2 mutation for treatment with TAZVERIK (tazemetostat), in accordance with the approved therapeutic product labeling. The statement reports this intended identification purpose but does not independently establish safety or clinical effectiveness. The applicant is Roche Molecular System, Inc., and the product code is OWD.

FDA approval order statement

Approval for The cobas EZH2 Mutation Test. The device is a real-time allele-specific PCR test for qualitative detection of single nucleotide mutations for Y646N, Y646F or Y646X (Y646H, Y646S, or Y646C), A682G, and A692V of the EZH2 gene in DNA extracted from formalin fixed paraffin embedded (FFPE) human follicular lymphoma tumor tissue specimens. The cobas EZH2 Mutation Test is intended for the identification of follicular lymphoma patients with an EZH2 mutation for treatment with TAZVERIK (tazemetostat), in accordance with the approved therapeutic product labeling.
Regulatory pathway
Original PMA
Clinical specialty
Pathology
Decision date
Jun 18, 2020

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P200014
Regulatory pathway
Premarket approval application
Product code
OWD
Decision code
APWD
Decision date
Jun 18, 2020
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Somatic gene mutation detection system.

Product code
OWD
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P200014 received

    Application receipt date recorded by FDA.

  2. P200014 · FDA decision

    APWD

  3. P200014/S012 · Related supplement

    cobas EZH2 Mutation Test

Timeline entries are records held by MedtechLedger for P200014. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200014

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Molecular System, Inc.PMA supplementOct 27, 2026FDA

Explore the linked device profile

Other records with product code OWD

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA
RochePMA supplementNov 4, 2026FDA
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
RochePMA supplementOct 27, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche Molecular System, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
4300 Hacienda Dr., Pleasanton, CA, 94588

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records